SUPERNUS PHARMACEUTICALS, INC. Impairment of Intangible Assets (Excluding Goodwill)
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Impairment of Intangible Assets (Excluding Goodwill) of $54.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-03
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $54.92M.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for the quarter ending 2023-12-31 was $20.20M.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $0.00.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $20.19M.
- SUPERNUS PHARMACEUTICALS, INC. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|
| 2026-06-30 | $54.92M 10-Q · filed 2026-08-03 | $54.92M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $0.00 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $20.20M 10-K · filed 2026-03-02 | $20.19M 10-K · filed 2026-03-02 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |